PD‐1/PD‐L1 inhibitors (dostarlimab, pembrolizumab, durvalumab, and atezolizumab) have demonstrated their efficacy when combined with TC as the first‐line treatment for endometrial cancer through randomized phase III clinical trials: RUBY; NRG‐GY018; DUO‐E; and AtTEnd.5, 6, 7, 8. Here, PDCD1 is linked to endometrial cancer.